Unlock instant, AI-driven research and patent intelligence for your innovation.

lxr inhibitors and uses thereof

A technology of inhibitors and uses, applied in the field of LXR inhibitors for the treatment of non-alcoholic fatty liver disease, and the field of drugs for the treatment of fatty liver disease, to achieve good treatment and remission efficacy, and to improve the effect of liver damage and steatosis.

Active Publication Date: 2020-07-14
浙江玉安康瑞生物科技有限公司
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Vitamin E and pioglitazone are often recommended for the treatment of patients with NASH (nonalcoholic steatohepatitis), however there are certain side effects

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • lxr inhibitors and uses thereof
  • lxr inhibitors and uses thereof
  • lxr inhibitors and uses thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0027] Example 1 Inhibition of Glabridin on LXR

[0028] Glabridin and LXR agonist (T0901317) were purchased from Shanghai Taosu Biochemical Technology Co., Ltd. pGADT7-SRC1, pGBKT7-LXR-LBD, etc. were prepared in advance in the laboratory by means of molecular cloning.

[0029] The inhibitory effect of glabridin on LXR was verified by yeast two-hybrid system. The yeast transformation method is as follows: Take a sterile 1.5ml EP tube, add in turn the pre-cooled target plasmid pGBKT7-LXR-LBD 2.5µg, pGADT7-SRC1 5µg, CarrierDNA 5µl, Y2HGold competent cells melted on ice 100µl, PEG / LiAc 500µl, gently invert and mix 6-8 times. Water bath at 30°C for 30 minutes, during which time, gently invert and mix 6-8 times every 10 minutes. Add 20 µl of DMSO to increase transformation efficiency. Afterwards, bathe in water at 42°C for 15 minutes, gently invert and mix 6-8 times every 5 minutes; centrifuge briefly at 12000rpm to discard the supernatant, resuspend with 100µl 0.9% NaCl solut...

Embodiment 2

[0037] Example 2 Molecular docking screening

[0038] Obtain the NMR structure of LXR (PDBID: 3IPQ) from the PDB database (http: / / www.rcsb.org / pdb / home / home.do), select the structure with the lowest energy and use Autodock Tools software to hydrogenate it and calculate Charge and other preprocessing. The active pocket is determined by Schroadinger software, and the Grid parameters are set to obtain 60×60×60Å 3 grid. The crystal structure was optimized using AutoDock Tools, including hydrogenation, deletion of water molecules, and completion of missing residues and side chains. After setting the Grid parameters, use autodock to perform rigid docking with the compound with optimized structure. Finally, PyMol software was used to visually analyze glabridin and its homologues, and the structure with the lowest energy was selected according to the scoring ranking and structural similarity to reduce the false positive rate, and the homologues of glabridin were initially screened ...

Embodiment 3

[0041] Embodiment 3 Animal experiments

[0042] The mice used in the experiment were healthy C57BL / 6 female mice (SPF grade) with a body weight of 20±2 g at 6-8 weeks. High-fat feed (87.8% normal feed + 10% lard + 2% cholesterol + 0.2% sodium cholate) and normal feed were provided by Shanghai Slack Experimental Animal Co., Ltd.

[0043] In order to verify the therapeutic effect of glabridin (GLA) on non-alcoholic fatty liver, 32 healthy C57BL / 6 female mice were adaptively fed for 1 week in the laboratory, and then they were divided into normal saline control group according to the random number table method. Group, model group, low-dose glabridin group (20ml / kg / d) and high-dose glabridin group (40mg / kg / d), 8 rats in each group.

[0044] The control group was fed with common feed, and the other groups were fed with high-fat feed (87.8% common feed + 10% lard + 2% cholesterol + 0.2% sodium cholate), with free intake of water and food. After 16 weeks, the feeding conditions of ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an LXR inhibitor. The LXR inhibitor comprises glabridin, a homologous compound of glabridin, an isomer of glabridin or a pharmaceutically acceptable salt. Application of the LXR inhibitor in treating non-alcoholic fatty liver disease and producing a medicine for treating non-alcoholic fatty liver disease is further provided. According to application of the LXR inhibitor in treating non-alcoholic fatty liver disease and producing the medicine for treating non-alcoholic fatty liver disease, an LXR is used as a target spot, glabridin and the homologous compound of glabridin are screened out, and interaction of the glabridin and the homologous compound of glabridin with the lipid metabolism-related gene LXR is proven through experiments, so that expression of the LXR is inhibited, non-alcoholic fatty liver damage is reversed, high fat diet-induced liver damage and the steatosis degree are effectively improved, and the LXR inhibitor has excellent treating and relieving efficacy for non-alcoholic fatty liver disease.

Description

technical field [0001] The invention relates to the field of pharmacy, in particular to medicines for treating fatty liver disease, in particular to LXR inhibitors which can be used for treating nonalcoholic fatty liver disease. Background technique [0002] Non-alcoholic fatty liver disease (NAFLD) is a genetic-environment-metabolic stress-related clinicopathological syndrome characterized by excessive liver fat accumulation without a history of excessive alcohol consumption. One of the main pathogenic mechanisms of NAFLD is lipid metabolism disorder, leading to lipid deposition, that is, the free fatty acids acquired by the liver exceed the liver's own processing capacity, resulting in triglyceride accumulation. The hallmark change of NAFLD is the accumulation of triglycerides in the cytoplasm of hepatocytes due to lipid acquisition (i.e., fatty acid uptake) and de novo lipid generation and removal (i.e., mitochondrial fatty acid oxidation and assembly of very low-density ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07D493/04A61P1/16A61P3/06A61K31/35
CPCA61K31/35A61P1/16A61P3/06C07B2200/07C07D493/04
Inventor 黄瑾曾乃燕姜玮赟
Owner 浙江玉安康瑞生物科技有限公司